Table 2.

Characteristics of patients with HAE.

No.	Sex, age range	HAE type*	Prophylactic treatment**	Last dose of prophylaxis before sampling	Sum of BK and fragments (pmol/L)
H1	F, 61–65	1	Berinert	2 weeks	16.46
H2	F, 66–70	2	None		1.70
H3	F, 21–25	1	Haegarda	1 day	8.28
H4	M, 71–75	1	Berotralstat	14 h	64.39
H5	F, 26–30	1	Haergarda	1 day	3.54
H6	F, 51–55	1	Haegarda + Berinert	2 days	8.56
H7	M, 61–65	1	Berotralstat	14 h	27.56
H8	F, 41–45	1	None		16.20
H9	F, 31–35	1	Berinert	2 days	15.17
F1	F, 46–50	F12 T328K	Tranexamic acid	2 h	11.82
F2***	M, 16–20	F12 T328K	None		1.60
F3	F, 41–45	F12 T328K	None		10.88
F4	F, 26–30	F12 T328K	None		9.72
F5	F, 36–40	F12 T328K	None		8.62
F6****	F, 51–55	F12 T328K	None		6.23
F7	F, 36–40	F12 T328K	None		3.05

^*Types 1 and 2 are variants of C1INH haplodeficiencies.

^**Berinert and Haegarda are C1INH concentrates.

^***Son of F1.

^****mother of F4, F5, F7.